Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM · IEX Real-Time Price · USD
33.04
-0.92 (-2.71%)
At close: Mar 28, 2024, 4:00 PM
33.90
+0.86 (2.60%)
After-hours: Mar 28, 2024, 7:50 PM EDT

Company Description

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.

Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.
Beam Therapeutics logo
Country United States
Founded 2017
IPO Date Feb 6, 2020
Industry Biotechnology
Sector Healthcare
Employees 507
CEO John M. Evans M.B.A.

Contact Details

Address:
510 Lake Cook Road
Deerfield, Illinois 60015
United States
Phone (847) 948-8888
Website beamtx.com

Stock Details

Ticker Symbol BEAM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0000789073
CUSIP Number 07373V105
ISIN Number US07373V1052
Employer ID 13-3295276
SIC Code 2080

Key Executives

Name Position
John M. Evans M.B.A. Chief Executive Officer and Director
Dr. Giuseppe Ciaramella Ph.D. President
Terry-Ann Burrell M.B.A. Chief Financial Officer and Treasurer
Dr. Feng Zhang Ph.D. Co-Founder
Dr. David R. Liu Ph.D. Co-Founder
Dr. J. Keith Joung M.D., Ph.D. Co-Founder
Dr. Nicole Gaudelli Ph.D. Co-Founder
Dr. Alexis Komor Ph.D. Co-Founder
Dr. Manmohan Singh Ph.D. Chief Technology Officer
Dr. Gopi Shanker Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
May 12, 2014 NO ACT Filing
May 12, 2014 NO ACT Filing
May 12, 2014 NO ACT Filing
May 12, 2014 NO ACT Filing
May 12, 2014 15-12B Securities registration termination
May 12, 2014 15-12B Securities registration termination
May 2, 2014 25 Filing
Apr 30, 2014 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 30, 2014 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 30, 2014 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments